BJDX
Bluejay Diagnostics, Inc.
Medical - Devices
Market Cap$334K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BJDX vs CUE
Revenue, margins, valuation, and 5-year total return — side by side.
CUE
Cue Biopharma, Inc.
Biotechnology
Market Cap$94M
5Y Perf.-90.3%
BJDX vs CUE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BJDX | CUE |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $334K | $94M |
| Revenue (TTM) | $0.00 | $27M |
| Net Income (TTM) | $-7M | $-27M |
| Gross Margin | — | 88.0% |
| Operating Margin | — | -96.6% |
| Total Debt | $222K | $4M |
| Cash & Equiv. | $4M | $27M |
BJDX vs CUE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BJDX
CUE
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Bluejay Diagnostics… (BJDX) | 100 | 0.0 | -100.0% |
| Cue Biopharma, Inc. (CUE) | 100 | 9.7 | -90.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BJDX vs CUE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CUE leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Bluejay Diagnostics, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BJDX
Bluejay Diagnostics, Inc.
The Income Pick
BJDX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.89
- Lower volatility, beta 0.89, Low D/E 3.9%, current ratio 6.05x
- Beta 0.89, current ratio 6.05x
Best for: income & stability and sleep-well-at-night
CUE
Cue Biopharma, Inc.
The Growth Play
CUE carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 195.7%, EPS growth 61.1%, 3Y rev CAGR 180.5%
- -89.8% 10Y total return vs BJDX's -100.0%
- 195.7% revenue growth vs BJDX's 19.8%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CUE | 195.7% revenue growth vs BJDX's 19.8% |
| Quality / Margins | BJDX | -10.2% margin vs CUE's -96.9% |
| Stability / Safety | BJDX | Beta 0.89 vs CUE's 2.34, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CUE | +55.0% vs BJDX's -73.5% |
| Efficiency (ROA) | CUE | -77.8% ROA vs BJDX's -140.1%, ROIC -5.4% vs -399.9% |
BJDX vs CUE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCUELAGGINGBJDX
BJDXBluejay Diagnostics, …
0leads
CUECue Biopharma, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs BJDXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CUE1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CUE6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CUE6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CUE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CUE and BJDX operate at a comparable scale, with $27M and $0 in trailing revenue.
| Metric | BJDXBluejay Diagnosti… | CUECue Biopharma, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $27M |
| EBITDAEarnings before interest/tax | -$7M | -$23M |
| Net IncomeAfter-tax profit | -$7M | -$27M |
| Free Cash FlowCash after capex | -$6M | -$22M |
| Gross MarginGross profit ÷ Revenue | — | +88.0% |
| Operating MarginEBIT ÷ Revenue | — | -96.6% |
| Net MarginNet income ÷ Revenue | — | -96.9% |
| FCF MarginFCF ÷ Revenue | — | -79.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.1% | +111.0% |
CUE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BJDX and CUE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BJDXBluejay Diagnosti… | CUECue Biopharma, In… |
|---|---|---|
| Market CapShares × price | $333,773 | $94M |
| Enterprise ValueMkt cap + debt − cash | -$4M | $71M |
| Trailing P/EPrice ÷ TTM EPS | -0.04x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.42x |
| Price / BookPrice ÷ Book value/share | 0.06x | 4.27x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BJDX and CUE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CUE leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CUE delivers a -165.2% return on equity — every $100 of shareholder capital generates $-165 in annual profit, vs $-186 for BJDX. BJDX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to CUE's 0.16x. On the Piotroski fundamental quality scale (0–9), CUE scores 5/9 vs BJDX's 2/9, reflecting solid financial health.
| Metric | BJDXBluejay Diagnosti… | CUECue Biopharma, In… |
|---|---|---|
| ROE (TTM)Return on equity | -185.5% | -165.2% |
| ROA (TTM)Return on assets | -140.1% | -77.8% |
| ROICReturn on invested capital | -4.0% | -5.4% |
| ROCEReturn on capital employed | -160.3% | -112.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.04x | 0.16x |
| Net DebtTotal debt minus cash | -$4M | -$23M |
| Cash & Equiv.Liquid assets | $4M | $27M |
| Total DebtShort + long-term debt | $222,249 | $4M |
| Interest CoverageEBIT ÷ Interest expense | -5972.19x | -74.29x |
CUE leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CUE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CUE five years ago would be worth $1,058 today (with dividends reinvested), compared to $0 for BJDX. Over the past 12 months, CUE leads with a +55.0% total return vs BJDX's -73.5%. The 3-year compound annual growth rate (CAGR) favors CUE at -37.6% vs BJDX's -94.4% — a key indicator of consistent wealth creation.
| Metric | BJDXBluejay Diagnosti… | CUECue Biopharma, In… |
|---|---|---|
| YTD ReturnYear-to-date | -30.5% | +253.1% |
| 1-Year ReturnPast 12 months | -73.5% | +55.0% |
| 3-Year ReturnCumulative with dividends | -100.0% | -75.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -89.4% |
| 10-Year ReturnCumulative with dividends | -100.0% | -89.8% |
| CAGR (3Y)Annualised 3-year return | -94.4% | -37.6% |
CUE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BJDX and CUE each lead in 1 of 2 comparable metrics.
Risk & Volatility
BJDX is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than CUE's 2.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CUE currently trades 86.3% from its 52-week high vs BJDX's 10.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BJDXBluejay Diagnosti… | CUECue Biopharma, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.89x | 2.34x |
| 52-Week HighHighest price in past year | $16.68 | $41.42 |
| 52-Week LowLowest price in past year | $0.78 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +10.9% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 70.8 |
| Avg Volume (50D)Average daily shares traded | 26K | 903K |
Evenly matched — BJDX and CUE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BJDXBluejay Diagnosti… | CUECue Biopharma, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CUE leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallCue Biopharma, Inc. (CUE)Leads 3 of 6 categories
Loading custom metrics...
BJDX vs CUE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BJDX or CUE?
Over the past 5 years, Cue Biopharma, Inc.
(CUE) delivered a total return of -89. 4%, compared to -100. 0% for Bluejay Diagnostics, Inc. (BJDX). Over 10 years, the gap is even starker: CUE returned -89. 8% versus BJDX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BJDX or CUE?
By beta (market sensitivity over 5 years), Bluejay Diagnostics, Inc.
(BJDX) is the lower-risk stock at 0. 89β versus Cue Biopharma, Inc. 's 2. 34β — meaning CUE is approximately 161% more volatile than BJDX relative to the S&P 500. On balance sheet safety, Bluejay Diagnostics, Inc. (BJDX) carries a lower debt/equity ratio of 4% versus 16% for Cue Biopharma, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — BJDX or CUE?
On earnings-per-share growth, the picture is similar: Cue Biopharma, Inc.
grew EPS 61. 1% year-over-year, compared to 42. 1% for Bluejay Diagnostics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BJDX or CUE?
Bluejay Diagnostics, Inc.
(BJDX) is the more profitable company, earning 0. 0% net margin versus -96. 9% for Cue Biopharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BJDX leads at 0. 0% versus -96. 7% for CUE. At the gross margin level — before operating expenses — CUE leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BJDX or CUE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is BJDX or CUE better for a retirement portfolio?
For long-horizon retirement investors, Bluejay Diagnostics, Inc.
(BJDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89)). Cue Biopharma, Inc. (CUE) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BJDX: -100. 0%, CUE: -89. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BJDX and CUE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BJDX is a small-cap quality compounder stock; CUE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.